BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
US Army

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,780,676

« Back to Dashboard

Summary for Patent: 5,780,676

Title: Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
Abstract:Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, pyrrole, and poiyenoic acid derivatives including carbocyclic polyenoic acids. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
Inventor(s): Boehm; Marcus F. (San Diego, CA), Heyman; Richard A. (Encinitas, CA), Zhi; Lin (San Diego, CA), Hwang; Chan Kou (San Diego, CA), White; Steve (San Diego, CA), Nadzan; Alex (San Diego, CA)
Assignee: Ligand Pharmaceuticals Incorporated (San Diego, CA)
Application Number:08/485,386
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Process; Use;

No matches for this query

International Patent Family for Patent: 5,780,676

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark0678087► Subscribe
Denmark0678086► Subscribe
Denmark0637297► Subscribe
European Patent Office0678087► Subscribe
European Patent Office0678086► Subscribe
European Patent Office0637297► Subscribe01C0027France► Subscribe
European Patent Office0637297► SubscribeSPC013/2001Ireland► Subscribe
European Patent Office0637297► SubscribeCA 2001 00032Denmark► Subscribe
European Patent Office0637297► SubscribeC300054Netherlands► Subscribe
European Patent Office0637297► SubscribeSPC/GB01/041United Kingdom► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Cantor Fitzgerald
Fish and Richardson
Federal Trade Commission
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: